期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗癌药——喜树碱衍生物 被引量：7

Camptothecin derivatives——a kind of antitumor agents
下载PDF
导出
摘要 概述了近年来临床抗癌良药喜树碱衍生物topotecan ,CPT 11和HCPT抗癌活性的发现、抗癌机制及其临床应用。 The antitumor activity and mechanisms and clinical uses of topotecan,CPT 11 and HCPT,some derivatives of camptothecin,were reviewed.
作者 李志勇 郭勇
机构地区 华南理工大学食品与生物工程学院
出处 《中国新药杂志》 CAS CSCD 2000年第9期598-601,共4页 Chinese Journal of New Drugs
关键词 喜树碱衍生物 抗癌药物 临床应用 抗癌活性 camptothecin analogue antitumor medicine clinical uses
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献13

  • 1RowePM.Camptothecin:newenthusiasmforanolddrug[J].Lancet,1995,347∶892-896.[3]GiovanellaBC,StehlinJS,WallME,etal.DNAtopoisomeraseItargetchemotherapyofhumancoloncancerxenografts[J].Science,1989,246∶1046-1050.
  • 2RowinskyEK,GrochowLB,HendricksCB,etal.PhaseIandpharmacologicstudyoftopotecan:anoveltopoisomeraseIinhibitor[J].JClinOncol,1992,10∶647-656.
  • 3SchillerJH,KimK,JohnsonD.PhaseⅡstudyoftopotecaninextensivestagesmallcelllungcancer[J].ProcAmSocClinOncol,1994,13∶330.
  • 4RobertF,WheelerRH,MolthropDC,etal.PhaseⅡstudyoftopotecaninadvancedheadandneckcancer:Identificationofanactivenewagent[J].ProcAmSocClinOncol,1994,13∶905.
  • 5EisenhauerEA,WainmanN,BoosG,etal.PhaseⅡtrialsoftopotecaninpatients(pts)withmalignantgliomaandsofttissuesarcoma[J].ProcAmSocClinOncol,1994,13∶175.
  • 6VerweijJ,LundB,BeijnenJ,etal.PhaseIandpharmacokineticsstudyoftopotecan,anewtopoisomeraseIinhibitor[J].AnnOncol,1993,4∶673-678.
  • 7MillerAA,HargisJB,LilenbaumRC,etal.PhaseIstudyoftopotecanandcisplatininpatientswithadvancedcancer:acancerandleukemiagroupBstudy[J].JClinOncol,1994,12∶2743-2750.
  • 8AbigergesD,ChabotGG,ArmandJP,etal.PhaseIandpharmacologicstudiesofthecamptothecinanalogueirinotecanadministeredevery3weeksincancerpatients[J].JClinOncol,1995,13∶210-221.
  • 9AbigergesD,ArmandJP,ChabotGG,etal.Irinotecan(CPT-11)high-doseescalationusingintensivehigh-doseloperamidetocontroldiarrhea[J].JNatlCancerInst,1994,86∶446-449.
  • 10王灏,胡伟国.羟基喜树碱治疗进展期大肠癌[J].中国癌症杂志,1998,8(1):63-64. 被引量：27

二级参考文献16

  • 1Rowe PM. Camptothecins: new enthusiasm for an old drug.Lancet, 1995,347:892.
  • 2Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.The current status of camptothecin analogues as antitumor agents,J Natl Cancer Inst,1993,85:271.
  • 3Bleiberg H. Colorectal cancer: the challenge, Eut J Cancer,1996,32(A Suppl 5):S2.
  • 4Labianca R, Pessi A, Facendola G, et al. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer:a critical review of comparative studies. Eur J Cancer,1996,32(A Suppl5):S7.
  • 5Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11(irinotecan) ad a single agent in metastatic colorectal cancer.Eur J Cancer,1996,32(A Suppl3):S13.
  • 6Wiseman LR, Markham A. Irinotecan. A review of its pharma cological properties and clinical efficacy in the management of advanced colorectal cancer.Drugs,1996,52:606.
  • 7Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer,1995,31(A Suppl 3):1283.
  • 8Cunningham D. Current status of colorectal cancer:CPT-11(irinotecan), a therapeutic innovation. Eur J Cancer, 1996,32(A Suppl 3):S1.
  • 9Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol,1996,23(1Suppl3):34.
  • 10Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan)and 5-fluorouracil:a promising combination for therapy of colorectal cancer. Eur J Cancer, 1996,32(A Suppl 3):S24.

共引文献26

同被引文献67

  • 1潘显道,王存英.天然抗肿瘤药喜树碱衍生物的研究进展[J].药学学报,2003,38(9):715-720. 被引量：31
  • 2陈军,方芸,张海霞,黄莉莉,钱晓萍,刘宝瑞.雾化吸入羟基喜树碱在兔体内的组织分布[J].药学学报,2004,39(9):747-751. 被引量：12
  • 3印嘉骏.戊柔沙星治疗卡介菌无效的膀胱原位癌的疗效和安全性[J].国外医学：药学分册,2000,27(5):308-308.
  • 4[2]Christian B. Homocamptothecins:potent topoisomerase I inhibitors and promising anticancer drugs[J]. Crit Rev Oncol Hematol, 2003 ;45( 1 ) :91 - 108
  • 5[3]Zhang RW, Li YF, Cai QY, Liu TP, Sun H. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I [ J ]. Cancer Chemother Pharmacol, 1998; 41: 257 - 67
  • 6[7]Ma J, Liu CL, Zhu PL, Jia ZP, Xu LT, Wang R. Simultaneous determination of the carboxylate and lactone forms of 10hydroxycamptothecin in human serum by restricted-access media high-performance liquid chromatography [J]. J Chromatogr B,2002; 772:197 - 204
  • 7[8]Zhou J J, Liu Jn, Xu B. Relationship between lactone ring forms of hcpt and their antitumor activities[J]. 中国药理学报,2001;22(9) :827 - 30
  • 8[11]Li YF, Zhang RW. Reversed-phase high-performance liquid chromatography method for the simultaneous quantitation of the lactone and carboxylate forms of the novel natural product anticancer agent 10-hydroxycamptothecin in biological fluids and tissues[J]. J Chromatogr B, 1996;686:257- 65
  • 9[12]Bom D, Curran DP, Zhang J, Zimmer SG, Bevins R, Kruszewski S, et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity [ J]. J Controlled Release, 2001; 74(6) :325 - 33
  • 10PATEL S H, AJLOUNI M, CHAPMAN R, et al. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non- small cell lung cancer (NSCLC) [ J ]. J Thorac Oncol, 2007, 2(9) : 831-837.

引证文献7

二级引证文献53

中国新药杂志
2000年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部